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ORIGINAL ARTICLE
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ABSTRACT
Bisphosphonates (BPs) are a mainstay of osteoporosis treatment; however, concerns about bone health based on oversuppression of
remodeling remain. Long-term bone remodeling suppression adversely affects bone material properties with microdamage accumulation and reduced fracture toughness in animals and increases in matrix mineralization and atypical femur fractures in patients.
Although a “drug holiday” from BPs to restore remodeling and improve bone quality seems reasonable, clinical BPs have long functional half-lives because of their high hydroxyapatite (HAP) binding afﬁnities. This places a practical limit on the reversibility and effectiveness of a drug holiday. BPs with low HAP afﬁnity and strong osteoclast inhibition potentially offer an alternative approach; their
antiresorptive effect should reverse rapidly when dosing is discontinued. This study tested this concept using NE-58025, a BP with low
HAP afﬁnity and moderate osteoclast inhibition potential. Young adult female C57Bl/6 mice were ovariectomized (OVX) and treated
with NE-58025, risedronate, or PBS vehicle for 3 months to test effectiveness in preventing long-term bone loss. Bone microarchitecture, histomorphometry, and whole-bone mechanical properties were assessed. To test reversibility, OVX mice were similarly treated
for 3 months, treatment was stopped, and bone was assessed up to 3 months post-treatment. NE-58025 and RIS inhibited long-term
OVX-induced bone loss, but NE-58025 antiresorptive effects were more pronounced. Withdrawing NE-58025 treatment led to the
rapid onset of trabecular resorption with a 200% increase in osteoclast surface and bone loss within 1 month. Cessation of risedronate
treatment did not lead to increases in resorption indices or bone loss. These results show that NE-58025 prevents OVX-induced bone
loss, and its effects reverse quickly following cessation treatment in vivo. Low-HAP afﬁnity BPs may have use as reversible, antiresorptive agents with a rapid on/off proﬁle, which may be useful for maintaining bone health with long-term BP treatment. © 2021 The
Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
KEY WORDS: ANALYSIS/QUANTITATION OF BONE; ANTIRESORPTIVES; BONE HISTOMORPHOMETRY; BONE MICRO-COMPUTED TOMOGRAPHY (μCT);
BONE MODELING AND REMODELING; BONE QUANTITATIVE (QCT); DISEASES AND DISORDERS OF/RELATED TO BONE; OSTEOPOROSIS; THERAPEUTICS

Introduction

B

isphosphonates (BPs) have been the standard antiresorptive
therapy used to prevent bone loss in osteoporosis for nearly
three decades.(1–3) They act by inhibiting osteoclastic bone resorption, which suppresses remodeling thereby maintaining bone
mass.(4,5) BPs are highly effective at reducing bone loss and preventing fractures in postmenopausal osteoporosis, men with osteoporosis, and patients receiving glucocorticoid treatments. Yet despite
their efﬁcacy in conserving bone mass and preventing osteoporotic
fractures, long-term suppression of bone remodeling can adversely

affect bone tissue material properties. The consequences of longterm BP use can include microdamage accumulation in bone,(6–8)
increases in matrix mineral content,(9–11) and loss of tissue microstructural heterogeneity,(12–14) all of which potentially contribute
to decreased material-level fracture resistance. Impaired bone quality after long-term suppression of remodeling has been found in
both animal models and tissues from patients treated for long
periods with BPs,(10–12,14,15) and is thought to underlie the atypical
femur fractures (AFFs) observed in some patients after long-term
treatment with antiresorptives.(16–19) As reviewed by Shane
et al,(20) the absolute risk of AFFs in patients taking BPs is low,
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ranging from 3.2 to 50 cases per 100,000 person-years. However,
long-term BP use is associated with a substantially higher risk of
AFF (100 per 100,000 person-years).
A temporary cessation of BP treatment, referred to as a “drug
holiday,” has been widely discussed in the clinical literature as a
means to restore bone remodeling and to recover bone material
properties; however, its efﬁcacy in restoring bone quality is
unclear.(21–27) A major challenge to implementing an effective
drug holiday strategy is that the leading BPs in current clinical
use (i.e., alendronate, risedronate (RIS), ibandronate, and zoledronate) have very long functional half-lives in vivo, although
some variation exists based on dose and speciﬁc compound.
As a result, many BPs can remain in bone tissue for periods estimated to be years in humans.(22,26,28)
The ability to “target” or bind to bone mineral is one of the
two principal criteria used to select BPs for development and
clinical use. It has been assessed quantitatively by measuring
binding afﬁnity for hydroxyapatites (HAPs) in vitro, acute skeletal
retention in vivo, or functional life in patients.(29–33) Among the
BPs in wide clinical use for preventing bone loss, zoledronate
and alendronate bind to bone mineral with the highest afﬁnity,
followed by ibandronate and then RIS.(29,31,34) The second criterion is the ability to inhibit osteoclast activity and its potency in
this respect is measured by the ability to inhibit farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway that is required for osteoclast rufﬂed border formation.(35,36)
Among the widely used clinical BPs, zoledronate and RIS are
more potent and thus prevent bone resorption at lower doses
than ibandronate or alendronate.(34,36) Finally, other reported
properties, including antiapoptotic activity,(37–40) safety,(41) and
skeletal distribution,(4,42,43) may contribute to the clinical effects
and usefulness of BPs.
Medicinal chemists have designed many variants of BPs over
the years that have advanced the understanding of structural
contributions to the pharmacological features of this drug class.
These developments have ultimately identiﬁed highly efﬁcacious BP drugs for development and clinical use. The key chemical feature of the BPs is the joining of two phosphonate moieties
by one central carbon. This P-C-P structure was found to be metabolically stable versus the P-O-P feature of the natural bone
metabolism regulator pyrophosphate; therefore, the BP chemical class provided useful drug candidates for systemic administration.(34,44) Both of these general chemical features uniquely
coordinate to calcium and to the major calcium phosphate mineral component of bone—HAP. Variants can be compared and
ranked for their bone afﬁnity, using various in vitro models comprised of calcium phosphate HAP crystals and mineral surfaces.(45) The BP structure also offers two additional binding
sites to the central carbon, which are of course not available on
the corresponding central divalent oxygen of pyrophosphate.
These substituents are often referred to as R1 and R2 groups
(Fig. 1), where one R group may be an additional calcium coordinating substituent, such as an –OH (hydroxyl) group that
enhances BP bone afﬁnity and is a characteristic substituent of
almost all leading BPs in clinical use today.(34,46,47) This extra
coordinating group offers a more rapid and greater propensity
for the distribution of a BP to bone surfaces because of tighter
binding to those surfaces. A second R group substituent typically
includes a nitrogen containing substituent, which if appropriately designed can offer an additional mineral binding site and
perhaps even more importantly can yield BPs that bind tightly to
a key enzyme target within osteoclasts (FPPS), leading to potent
osteoclast inhibition and antiresorptive properties.(3,35,47) Groups,
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such as pyridyl alkyl, imidazole alkyl, and amino alkyl, are typical
substituents leading to structures such as RIS, zoledronate, and
alendronate, respectively.
There is a subset of BPs that is comprised of potent FPPS inhibitors, which have low HAP binding afﬁnity. These FPPS inhibitors
should have the potential to prevent bone loss.(30,36,48) However,
their low HAP afﬁnity could be hypothesized to allow these
agents to clear more rapidly from the skeleton when dosing is
stopped.(33) In principle, this would allow bone remodeling to
resume quickly and permit bone quality to recover; however,
the use and reversibility of such potentially reversible BPs have
not been well characterized in vivo. NE-58025 (cis-octahydro1-pyrindine-6, 6-bisphosphonic acid; Fig. 1), a BP created by our
coauthor (FHE) and initially reported in 1990 with good acute
in vivo antiresorptive activity, meets these key criteria. This
allows for an in vivo proof-of-concept test for a reversible BP with
low HAP binding afﬁnity and high FPPS inhibition.(49,50)
NE-58025 has a relatively high FPPS inhibitory potency, as do
other clinically used BPs, such as zoledronate and RIS.(36,51) The
R1 and R2 groups of NE-58025 are incorporated into a cycloalkyl
group that results in a lower bone afﬁnity, likely by sterically limiting the binding of the phosphonate groups to calcium on
HAP.(49,50) The low HAP binding afﬁnity of NE-58025 suggests
that it should be more rapidly reversible than higher afﬁnity, clinically used BPs once dosing stops, thus it is potentially valuable
for exploring the on–off usefulness of such agents. Little is
known about the efﬁcacy of NE-58025 in preventing long-term
bone loss; so far there are no in vivo data on its potential
reversibility.
Here, we tested the effectiveness of low HAP binding afﬁnity
BPs (i.e., NE-58025) in preventing long-term bone loss after estrogen withdrawal in mice. Changes in trabecular bone, cortical
bone, and whole-bone mechanical properties were assessed.
We then determined the time course of bone loss with
NE-58025 versus RIS and the extent of reversibility after stopping
long-term treatment with these two agents by assessing reactivation of resorption and bone loss.

Materials and Methods
Bisphosphonates
NE-58025 (cis-octahydro-1-pyrindine-6, 6-bisphosphonic acid), a
BP with low HA afﬁnity but with an osteoclast inhibition potency
similar to RIS, was created by our coauthor (FHE) at Norwich
Eaton Pharmaceuticals and initially reported in 1990.(49) RIS was
purchased from Sigma-Aldrich. The rationale for choosing RIS
was that NE-58025 is reported in the literature as a general structural analogue with even lower binding afﬁnity than RIS. In addition, human and rodent studies found that resorption indices
show a more rapid rebound when RIS treatment is stopped than
when other BPs (i.e., alendronate, zoledronate) treatments are
suspended.(22,23,52,53) Thus, using RIS as our reference point let
us gain insight into whether the rapid reversal effect we hypothesized for NE58025 would be better than that of clinical BPs in
terms of reversibility.

Mice
Young adult, female C57BL/6 mice (15 weeks old) were from the
Jackson Laboratory. Mice underwent surgical ovariectomy (OVX)
to induce estrogen deﬁciency, following procedures detailed
elsewhere.(54) OVX, sham-OVX, baseline, and age-matched
JBMR Plus (WOA)

Fig 1. Chemical structure for risedronate and NE-58025. The general structure for bisphosphonate has a phosphate–carbon–phosphate backbone, a R1
and a R2 group. R1, usually a hydroxyl group, is responsible for the afﬁnity to hydroxyapatite; R2 accounts for the differences in potency.

Table 1. Mouse Body Weights at Baseline and 3 Months After Ovariectomy
Parameter
Weight, g

Baseline
22.4  1.3

OVX/PBS

OVX/NE-025
*

29.1  1.4

*

27.8  1.3

OVX/RIS
28.4  1.8

Age-matched control (7 mo)
*

24.6  2.5*

Treatments with vehicle (OVX/PBS), NE-58025 (OVX/NE-025), or risedronate (OVX/RIS) treatment. Data shown as mean  SD.
Abbreviations: OVX = Ovariectomy; RIS = risedronate.
*p = 0.001 for OVX/PBS, OVX/NE-025, and OVX/RIS vs baseline control; p = 0.002 for age-matched control vs baseline.

controls were examined. All procedures were performed following Institutional Animal Care and Use Committee approval.

Experiment 1. Short-term prevention of bone loss by
NE-58025
In the ﬁrst studies, we tested the efﬁcacy of NE-58025 in preventing bone loss after estrogen withdrawal. Following OVX, mice
(N = 9-10/group) were treated for 3 weeks with either PBS or
NE-58025 in PBS vehicle at pH 7.4. The least effective dose
expected to prevent bone loss for NE-58025 was previously
reported to be in the range of 50–100 μg/kg of body
weight.(49,50) For comparison, the dose of RIS used to prevent
OVX-induced bone loss in rodents has been reported in the
range of 0.8–2.4 μg/kg.(52,55) NE-58025 was administered by sc
injection at 100 or 200 μg/kg daily; in addition, we examined
the effect of intermittent treatment (100 μg/kg given 3 days/
week; alternate days). Treatment continued for 3 weeks postOVX. Naïve 15-week-old mice were used as baseline controls
and naïve aging controls (n = 5) were examined as well. During
the study, mice had access to normal rodent chow and water
ad libitum. Bone ﬂuorochrome labels (calcein, 15 mg/kg ip;
Sigma-Aldrich) were given 9 and 2 days before the end of the
studies. After euthanasia, the right femurs and tibia were ﬁxed
in 10% neutral buffered formalin and used for bone
JBMR® Plus

histomorphometry. Left femurs and tibia were frozen at −20 C
for μCT studies as described below.

Experiment 2. Long-term suppression of bone loss and
reversibility: Comparison of NE-58025 and risedronate
In the second experiment, we (i) tested the long-term efﬁcacy of NE58025 in preventing bone loss after OVX based on the dose determined in Expt 1 and (B) assessed the time course and extent of reversibility after long-term treatment with NE-58025 versus RIS. For the
long-term prevention study (Expt 2A), female B6 mice underwent
OVX surgery as described in Expt 1. The BP treated mice received
either NE-58025 or RIS (n = 5/group). OVX/NE-58025 mice received
200 μg/kg/day sc (PBS vehicle), the effective dose for preventing
bone loss as determined in Expt 1. OVX/RIS mice were injected at
2.4 μg/kg sc (PBS vehicle), which has been reported to be 2–3 times
the dose needed to prevent bone loss in ovariectomized rats.52,55)
This RIS dose is the same as thatusedby Fuchs etal(52) in their rat studies for BP reversibility. Mice were weighed weekly and per mouse BP
doses adjusted if needed. The remaining group of OVX mice (n = 5)
were injected with PBS vehicle. Age-matched controls and shamoperated mice were examined as well (n = 5/group). For these
long-term bone loss prevention studies, mice were treated for
3 monthsandtheneuthanizedfor μCT,biomechanics,andhistomorphometric analyses. For the bisphosphonate withdrawal - reversibility studies (Expt 2B), NE-58025 or RIS treatment was carried out in
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Fig 2. Changes in cancellous bone volume and bone cell surface measurements for short-term NE-58025 studies to determine effective dose for preventing
OVX-induced bone loss. Graphs A-C show architectural changes from μCT analyses. All comparisons expressed versus baseline controls. (A) Bone volume fraction
(BV/TV) decreased signiﬁcantly after ovariectomy (OVX) in OVX/PBS, OVX/100 μg/kg, 3 days/week and OVX/100 μg/kg, 7 days/week (*p = 0.0001 for OVX/PBS
and p = 0.0003 for OVX/100 μg/kg and OVX/100 μg/kg, 7 days/week). NE-58025 given at 200 μg/kg, 7 days/week prevented OVX-induced bone loss (p = 0.24).
(B) Trabecular thickness (Tb.Th) decreased in all OVX groups (*p = 0.003 for OVX/PBS, p = 0.01 for OVX/100 μg/kg 3 days/week and p = 0.001 for OVX/100 μg/kg
and OVX/200 μg/kg 7 days/week. (C) Trabecular number (Tb.N) was reduced for OVX/PBS, OVX/100 μg/kg 3 days/week and OVX/100 μg/kg 7 days/week
(*p = 0.0001, p = 0.004, and p = 0.003, respectively). (D) Osteoclast surface/bone surface (Oc.S/BS) did not differ among all groups. (E) Eroded surface/bone surface
(ES/BS) increased within 3 weeks post-OVX in vehicle-treated mice (*p = 0.004). There were no differences among groups in (F) osteoblast surface/bone surface
(Ob.S/BS), (G) osteoid surface/bone surface (OS/BS), or (H) osteoid width (Osteoid Wi). Data shown as mean  SD.

Table 2. Cancellous Bone-Labeled Surface Measurements After 3 Weeks of NE-58025 (NE-025) Treatment Including MS/BS and MAR
Parameter
MS/BS, %
MAR, μm/d

Baseline
11.0  0.9
0.52  0.1

OVX/NE-025 100 μg/kg

OVX/PBS
33.8  6.9
0.78  0.2

*

*

27.8  9.6
0.55  0.1

OVX/NE-025 200 μg/kg

Age-matched control (18 wk)

22.2  1.9
0.94  0.4

32.9  3.5*
0.97  0.4

Comparisons vs baseline control. Data shown as mean  SD.
Abbreviations: MAR = mineral apposition rate; MS/BS = mineralizing surface/bone surface; OVX = ovariectomy.
*p = 0.004 for OVX/PBS, p = 0.02 for OVX/NE-025, and p = 0.001 for age-matched control.

OVX mice for 3 months, as above. Treatment was then stopped and
groups of mice (n = 5) were then sacriﬁced each month up to
3 months posttreatment. Mice were weighed weekly and BP doses
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adjusted as needed. Throughout the studies, mice had access to normal rodent chow and water ad libitum. Bone ﬂuorochrome labels
(calcein, 15 mg/kg ip) were given 9 and 2 days before sacriﬁce.
JBMR Plus (WOA)

Fig 3. Changes in cancellous bone at 3 months post-OVX with NE-58025 (NE-025) or RIS treatment. (A) Longitudinal and three-dimensional μCT
images of distal femurs for baseline, 3-month treatment groups, and age-matched controls (7 months old). Scale bar = 0.5 mm. Graphs B-D show
architectural changes from μCT analyses. All comparisons versus baseline control. (B) Decrease in trabecular bone volume fraction caused by
OVX was prevented with NE-025 (p = 0.5) but not with risedronate treatment (*p = 0.0001 for OVX/PBS, p = 0.048 for OVX/RIS, p = 0.003 for agematched control). (C) Trabecular thickness decreased as a result of OVX (*p = 0.001 for OVX/PBS) and aging (*p = 0.009 for age-matched control).
Tb.Th did not decline with NE-025 treatment and slightly decreased with RIS (*p = 0.003). (D) Trabecular number decreased by 70% in OVX/PBS mice
(*p = 0.0001) and 40% for age matched controls (*p = 0.006). Graphs E-I show changes in resorption and formation indices. (E) Osteoclast surface
was decreased slightly for OVX/RIS (*p = 0.04). (F) Eroded surface increased for all groups (*p = 0.02 for OVX/PBS, p = 0.001 for OVX/NE-025, p = 0.02
for OVX/RIS and p = 0.0001 for age matched controls). For OVX/PBS mice, formation indices increased signiﬁcantly. (G) Osteoblast surface
(*p = 0.002). (H) Osteoid surface (*p = 0.0001 for OVX/PBS, p = 0.04 for OVX/NE-025 and p = 0.03 for age-matched controls). (I) Osteoid width
(*p = 0.002). Data shown as mean  SD. BV/TV = trabecular bone volume fraction; ES/BS = eroded surface/bone surface; Ob.S/BS = osteoblast surface/bone surface; Oc.S/BS = osteoclast surface/bone surface; OS/BS = osteoid surface/bone surface; Osteoid Wi = osteoid width; OVX = ovariectomy; RIS = risedronate; Tb.Th = trabecular thickness; Tb.N = trabecular number.

JBMR® Plus
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Fig 4. Toluidine blue-stained bone sections of cancellous bone. (A) Shows a large osteoclast (arrows) on bone surface from long-term OVX/NE-025 treated
bone; the cell is not located within a Howship’s lacuna. (B) Shows several osteoclasts within Howship’s lacunae at 1 month after stopping treatment (OVX/
NE- 025 + 1-month reversal). (C) Shows extensive eroded surface and a large osteoclast (arrow) that appears close to perforating through the trabecular
element at 2 months after treatment cessation (OVX/NE-025 + 2-month reversal). Scale bar = 20 μm.

Table 3. Cancellous Bone-Formation Indices at (A) 3 Months Post-OVX With NE-58025 (NE-025) or RIS Treatment (Comparisons vs Baseline Control: *p = 0.003 for OVX/PBS, p = 0.007 for OVX/NE-025 and p = 0.001 for OVX/RIS), and (B) up to 3 Months After Stopping Bisphosphonate Treatment
(A)
Parameter
MS/BS, %
MAR, μm/d

Baseline
11.0  0.9
0.52  0.1

OVX/PBS

OVX/NE-025
*

32.7  4.1
0.81  0.2

*

24.2  3.7
1.15  0.4*

OVX/RIS

Age-matched control (7 mo)
*

35.2  4.6
1.6  0.5*

22.4  5.2
0.97  0.3

(B)
Parameter
MS/BS, %
MAR,
μm/d

OVX/NE-025,
+1 mo

OVX/NE-025,
+2 mo

OVX/NE-025,
+3 mo

OVX/RIS,
+1 mo

OVX/RIS,
+2 mo

OVX/RIS,
+3 mo

Age-matched control
(10 mo)

13.7  5.7***
0.78  0.38

21.5  7.2
0.81  0.24

25.2  4.9
0.98  0.1

12.0  9.3**
0.92  1.24

18.6  8.9**
1.75  0.91

32.9  5.6
1.01  0.2

35.0  5.1
0.73  0.5

Data shown as mean  SD.
Abbreviations: MAR = mineral apposition rate; MS/BS = mineralizing surface/bone surface; OVX = ovariectomy; RIS = risedronate.
Comparisons vs 3 mo of RIS treatment (OVX/RIS): **p = 0.002 for OVX/RIS, +1 mo, p = 0.01 for OVX/RIS, +2 mo. ***p = 0.03 for OVX/NE-025 + 1 mo vs
3 mo of NE-58025 treatment.

Femurs and tibia were harvested and processed as in the short-term
study discussed above.

μCT imaging
MicroCT studies were performed to assess bone microarchitecture. Femurs were scanned using the SkyScan 1172 system
(Bruker microCT) at a nominal isotropic voxel resolution of
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6.7 μm. Images were acquired using a 10-MP detector, 10-W
power energy setting (100 KV and 100 mA), and a 0.5-mm aluminum ﬁlter to minimize beam-hardening effects by ﬁltering lowenergy photons. An alignment procedure and ﬂat-ﬁeld detector
calibration were performed before each scan to minimize ring
artifacts and increase signal-to-noise ratio. Imaging, ﬁltering
and thresholding were performed following previous
studies.(56–58) HAP phantoms of known densities (0.25 and
JBMR Plus (WOA)

Table 4. Cortical Bone Architecture: (A) At 3 Months Post-OVX of NE-58025 (NE-025) or RIS Treatment, and (B) up to 3 Months After Stopping Bisphosphonate Treatment
(A)
Parameter
Ct.Ar/Tt.Ar, %
Tt.Ar, mm2
Ct.Ar, mm2
Ma.Ar, mm2
J, mm4

Baseline

OVX/PBS

OVX/NE-025

OVX/RIS

Age-matched
control (7 mo)

45.19  1.9
1.71  0.15
0.77  0.05
0.94  0.1
0.35  0.05

41.61  0.93*
1.78  0.07
0.74  0.04
1.04  0.03*
0.34  0.03

45.47  1.16
1.74  0.06
0.79  0.01
0.95  0.05
0.36  0.02

43.57  1.79
1.76  0.08
0.77  0.04
0.99  0.06
0.35  0.03

46.93  0.93
1.71  0.98
0.80  0.05
0.91  0.05
0.36  0.04

(B)

Parameter

OVX/NE-025,
+1 mo

OVX/NE-025,
+2 mo

OVX/NE-025,
+3 mo

OVX/RIS,
+1 mo

OVX/RIS,
+2 mo

OVX/RIS,
+3 mo

Agematched
control
(10 mo)

Ct.Ar/Tt.Ar, %
Tt.Ar, mm2
Ct.Ar, mm2
Ma.Ar, mm2
J, mm4

43.92  0.52
1.74  0.07
0.76  0.03
0.98  0.05
0.34  0.02

40.61  1.99**
1.83  0.1
0.74  0.02
1.09  0.09**
0.36  0.03

45.13  0.81
1.9  0.05**
0.86  0.03
1.05  0.06
0.42  0.02**

43.28  2.15
1.82  0.08
0.79  0.06
1.03  0.05
0.38  0.04

39.54  1.1***
1.91  0.11***
0.75  0.04
1.15  0.08***
0.38  0.04

40.44  1.77***
1.98  0.11***
0.8  0.01
1.18  0.1***
0.42  0.03***

45.87  1.52
1.8  0.09
0.83  0.02
0.98  0.07
0.38  0.03

Data shown as mean  SD. (A) Ovariectomy resulted in almost a 10% decrease in Ct.Ar/Tt.Ar after 3 mo (*p = 0.004 vs baseline control) and an increase
in Ma.Ar (*p = 0.02 vs baseline control), whereas bisphosphonate treatment prevented this bone loss. (B) NE-58025 mice experienced increases in Tt.Ar
and J after 3 mo of stopping treatment (**p = 0.01 for Tt.Ar, p = 0.02 for J vs OVX/NE-025). Two mo after stopping RIS treatment there were reductions in
Ct.Ar/Tt.Ar (***p = 0.005 for OVX/RIS + 2 mo, p = 0.03 for OVX/RIS + 3 mo vs OVX/RIS) and Tt.Ar (***p = 0.02 for OVX/RIS + 2 mo, p = 0.003 for OVX/RIS + 3
mo vs OVX/RIS). J increased by 3 mo after stopping RIS treatment (***p = 0.007 vs OVX/RIS).
Abbreviations: Ct.Ar = Cortical area fraction; J = polar moment of inertia; Ma.Ar = marrow area; OVX = ovariectomy; RIS = risedronate; Tt.Ar = total crosssectional area.

Table 5. Resorption Activity and Labeled Bone Surfaces of Cortical Bone: (A) After 3 Months of NE-58025 or RIS Treatment, and (B) After
Stopping Bisphosphonate Treatment
(A)
Parameter
Ec. ES/BS, %
Ec. MS/BS, %
Ec. MAR, μm/d

Baseline
2.73  2.1
7.05  4.3
0

OVX/PBS
*

12.96  2.8
5.64  2.4
0

OVX/NE-025

OVX/RIS

Age-matched control (7 mo)

Sham (7 mo)

3.19  4.1
1.0  2.2**
0

0.60  0.9
3.66  4.5
0.17  0.4

4.17  4.0
18.03  5.8
0.07  0.1

2.22  4.2
1.0  1.6
0

(B)
Parameter
Ec. ES/BS, %
Ec. MS/BS, %
Ec. MAR, μm/d

OVX/NE-025,+1 mo

OVX/NE-025,+2 mo

OVX/RIS,+1 mo

OVX/RIS,+2 mo

Age matched ctrl (10 mo)

2.68  0.8
6.36  3.1
0

2.95  2.8
15.53  7.4
1.12  1.2**

3.70  2.1
4.10  4.9
0

3.95  6.0
7.34  7.7
1.76  2.5

2.63  2.5
19.3  9.7
1.81  1.3

Data presented as mean  SD. (A) Ovariectomy resulted in an increase in ES/BS (*p = 0.04 vs baseline control). ** p = 0.02 for OVX/NE-025 for Ec. MS/BS.
(B) Data for NE-58025 mice showed an increase in MAR after 2 mo (**p = 0.003 vs OVX/NE-025).
Abbreviations: Ec. ES/BS = Endocortical eroded surface; Ec. MAR = endocortical mineral apposition rate; Ec. MS/BS = endocortical mineralizing surface/
bone surface; OVX = ovariectomy; RIS = risedronate.

0.75 g/cm3) and cross-sectional dimensions similar to that of a
mouse femur (2 mm diameter) were included in each scan. 3D
reconstructions were obtained using a customized backprojection algorithm (NRecon v1.6; Bruker, Belgium) with the
following reconstruction parameters: post-alignment compensation to optimize the center of rotation, smoothing correction kernel size of 1 pixel for asymmetrical boxcar window, ring artifact
correction set to 10, beam hardening correction (40%). All settings were kept constant throughout each scan reconstruction.
The μCT gray-scale data set was transformed into Hounsﬁeld
units (HUs), deﬁning a HU value of 0 for saline and a HU value
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of −1000 to black pixels (air). The linear relationship between
the HU and the HAP calibration phantoms was used to determine voxel tissue-mineral densities. Global thresholding was
performed by setting a bone-equivalent threshold to 0.45 g/cm3
for all scans as per Palacio-Mancheno et al.(56)
CT Analyzer software (version 1.13; Bruker) was used for measuring cortical and trabecular microarchitecture. Analyses were performed by one of two observers (AC, JB-P) who were blinded to
specimen identity. For trabecular bone, trabecular bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular number
(Tb.N) were measured in the metaphysis at a set distance from the
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Table 6. Biomechanical Data from Femoral Bending Tests: (A) at 3 Months Post-OVX With NE-58025 (NE-025) or RIS Treatment and (B)
After Stopping Bisphosphonate Treatment
(A)
Parameter
Stiffness, N/mm
Ultimate force, N
Postyield displacement, mm

Baseline

OVX/PBS

OVX/NE-025

OVX/RIS

Age matched control (7 mo)

103.9  12.2
28.4  4.3
0.25  0.1

105.9  32.9
25.7  1.4
0.22  0.01

130.1  41.2
29.73  4.0
0.21  0.05

118.7  29.4
25.35  1.4
0.17  0.04

140.1  31.2
29.5  2.2
0.17  0.05

(B)
Parameter

OVX/NE-025,
+1 mo

OVX/NE-025,
+2 mo

OVX/RIS,
+1 mo

OVX/RIS,
+2 mo

Age Matched Control
(10 mo)

Stiffness, N/mm
Ultimate force, N
Postyield displacement, mm

104.7  27
24.66  2.08
0.19  0.05

149.7  27.3
28.85  2.58
0.22  0.08

110.8  30.9
22.87  4.1
0.18  0.07

121.2  35.5
26.04  2.25
0.20  0.07

102.1  17.8
29.98  4.42
0.14  0.08

Data shown as mean  SD.
Abbreviations: OVX = Ovariectomy; RIS = risedronate.

distal process of the metaphyseal growth plate. Trabecular bone volume of interest (VOI) was deﬁned as 10% of the bone length. In longterm bone-loss prevention studies (mouse aged 4–7 months), we
observed increases in femur lengths for all groups compared with
baseline. The small amount of elongation of femurs in control groups
(400  150 μm vs baseline) is not unexpected given that the growth
plate at the distal femur remained open at the start of these studies.
We observed a greater amount of elongation in OVX mice with
femurs increasing in length by 750  140 μm vs baseline. This is consistent with Wronski et al who reported that OVX and estrogen withdrawal leads to elongation of long bones in young adult rodents
because estrogen loss delays growth plate closure.(59,60) Increases
in bone length over the course of the study were unaffected by BP
treatment. Finally, there was no consistent increase in bone length
during the 3-month period after stopping BP treatment (mouse aged
7–10 months). Antiresorptives, like BPs, are known to prevent the
developmentally programmed resorption and reduction in trabecular number that normally occurs just below the growth plate, which
results in an increase in bone volume that does not reﬂect anabolic
activity.(61,62) To compensate for the increase in bone length and to
avoid artifactually elevated measurements of bone volume in OVX
and control mice in these long-term studies, we shifted the trabecularbone μCT measurement region awayfromthegrowthplate bythe
average elongation distance for each group (750 and 400 μm for
OVX and controls, respectively). This correction assumed that most
of the bone elongation occurred at the distal femoral growth plate
in these mice, which was reasonable given the femoral head growth
plate in mice starts to fuse by approximately 4 months of age.(63) Cortical bone was analyzed at the mid-diaphyseal region (mid-diaphysis
5% of bone length), and total cross-sectional area (Tt.Ar), cortical
bone area (Ct.Ar), cortical area fraction (Ct.Ar/Tt.Ar), and polar of inertia (J) were measured.

Bone histomorphometry
Right femurs and tibias were ﬁxed in 10% neutral buffered formalin,
dehydrated, and embedded in methyl methacrylate. For trabecular
bone, longitudinal 5–7-μm thick sections were cut from the metaphyseal regions using a Leica Supercut microtome equipped with
a tungsten carbide knife. Eroded surface/bone surface (ES/BS; %),
osteoclast surface/bone surface (Oc.S/BS; %), osteoblast surface/
bone surface (Ob.S/BS; %), and osteoid surface/bone surface
(OS/BS; %) were measured on toluidine blue-stained sections. For
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cortical bone, cross sections were cut at a thickness of 200 μm from
the mid-diaphysis using a diamond wafering saw (Leica SP 1600)
and polished to 90 μm. Bone ﬂuorochrome labeling (mineral appositional rate [MAR]; μm/day) and mineralizing surface/bone surface
[MS/BS]; %) were measured from unstained sections for both cancellous and cortical bone. Histomorphometry measurements were
made using an OsteoMeasure system and were made by a single
observer who was blinded to section identity.

Biomechanical testing
Four-point bending to failure was used to test whole-bone mechanical properties. Left femurs were thawed and equilibrated in PBS at
room temperature for 2 hours before undergoing testing. Intact
bones were positioned in the test apparatus with the posterior side
in compression and anterior side in tension. Bending tests were
conducted in the posterior-to-anterior direction with a rate of
0.05 mm/s using the Bose ElectroForce 3200 system (Bose Corp) following procedures previously reported from our laboratory.(64–66)
Span lengths for inner- and outer-contact points were 2.2 and
6.35 mm, respectively. Whole-bone mechanical properties, including stiffness, yield point (deﬁned using a 10% offset method), ultimate load, energy to fracture, and postyield displacement, were
determined from load-displacement curves using a custom-written
software code in MatLab (MathWorks).

Statistical analyses
Comparisons were preformed using Kruskal-Wallis nonparametric test with Dunn’s post hoc test. In experiments 1 and 2A, the
primary comparisons were made against baseline controlto test
for drug efﬁcacy in preventing bone loss. Differences in the BP
withdrawal studies (experiment 2B) were assessed relative to
the respective 3-month treatment groups (OVX/NE-58025 or
OVX/RIS), which were deﬁned as the starting points for the BP
reversal studies. GraphPad Prism software (GraphPad) was used
for all statistical analyses. Data are reported as mean  SD.

Results
Mice tolerated all procedures well and there were no signiﬁcant
differences in body weights noted among BP and age-matched
groups during the short-term or long-term BP studies. As
JBMR Plus (WOA)

expected, body weights increased approximately 25% in OVX
mice during the long-term studies. These increases were similar
in BP and PBS vehicle-treated mice (p = 0.001; Table 1).

Experiment 1: Short-term prevention of bone loss after
OVX with NE-58025
OVX resulted in signiﬁcant trabecular bone loss (45%) over the
3-week period versus control (p = 0.0001; Fig. 2A). NE-58025 treatment at 100 μg/kg for 3 or 7 times per week attenuated but did
not prevent bone loss after OVX (p = 0.0003 vs baseline control).
In contrast, NE-58025 given daily at 200 μg/kg successfully prevented this bone loss; BV/TV was not signiﬁcantly different from
baseline control (p = 0.24), and there was no increase in eroded surface versus baseline controls (Fig. 2D,E). Bone formation parameters

did not differ for OVX/NE-58025 given daily at 200 μg/kg versus
baseline control bones (Table 2). BP treatment has no effect on bone
in shams; these data are summarized in Supplemental Table S1.
Based on these results, the 200 μg/kg/day dose of NE-58025 was
used for the long-term prevention and reversal studies.

Experiment 2A: Long-term prevention of bone loss after
OVX using NE-58025 or RIS
Trabecular bone
OVX resulted in an approximately 80% reduction in BV/TV versus
baseline control (Fig. 3B) in the 3 months following estrogen
withdrawal with corresponding decreases in trabecular thickness (−20%; Fig. 3C) and trabecular number (−65%; Fig. 3D).

Fig 5. Long-term changes in cancellous bone after stopping bisphosphonate treatment in OVX mice; data shown for 1, 2, and 3 months after stopping NE-58025
(NE-025) or RIS treatment. Graphs A-C show changes in trabecular bone architecture from μCT analyses and graphs D-H show changes in osteoclast and osteoblast
indices. Comparisons are versus the 3-month OVX/treatment-starting points. Data shown as mean  SD. (A) Cessation of NE-025 treatment led to rapid onset of
trabecular bone loss with a signiﬁcant reduction in BV/TV starting within 1 month. (#p = 0.03 for OVX/NE-025 + 1-month reversal; p = 0.04 for OVX/NE-025 + 2month reversal and p = 0.003 for OVX/NE-025 + 3-month reversal). Stopping RIS treatment did not result in bone loss. (B,C) Bone loss was principally caused by
a reduction in Tb.N. (D) Stopping NE-58025 treatment resulted in a 200% increase in Oc.S/BS within 1 month and a 250% increase by 2 months (#p = 0.04 for
OVX/NE-025 + 1-month reversal and p = 0.02 for OVX/NE-025 + 2-month reversal), and (E) ES/BS increased within 2 months of stopping treatment (p = 0.08). (F)
Osteoblast surface was signiﬁcantly decreased after 1 and 2 months of NE-58025 reversal (#p = 0.009 for OVX/NE-025 + 1-month reversal and p = 0.001 for
OVX/NE-025 + 2-month reversal). Ob.S/BS also decreased after 1 and 2 months of reversal for RIS groups (‡p = 0.0002 for OVX/RIS + 1-month reversal and
p = 0.02 for OVX/RIS + 2-month reversal). (G) OS/BS declined for all time points of reversal for NE-58025 (#p = 0.008 for OVX/NE-025 + 1-month reversal,
p = 0.001 for OVX/NE-025 + 2 -month reversal, and p = 0.03 for OVX/NE-025 + 3-month reversal) and RIS (‡ p = 0.0002 for OVX/RIS + 1-month reversal, p = 0.03
for OVX/RIS + 2-month reversal, and OVX/RIS + 3-month reversal). (H) Osteoid Wi decreased at 1 and 2 months of reversal (‡p = 0.002 for OVX/RIS + 1-month reversal and p = 0.04 for OVX/RIS + 2-month reversal). BV/TV = trabecular bone volume fraction; ES/BS = eroded surface/bone surface; Ob.S/BS = osteoblast surface/bone
surface; Oc.S/BS = osteoclast surface/bone surface; OS/BS = osteoid surface/bone surface; Osteoid Wi = osteoid width; OVX = ovariectomy; RIS = risedronate; Tb.Th =
trabecular thickness; Tb.N = trabecular number.
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Bone loss did not occur in OVX mice treated with NE-58025.
Long-term RIS treatment reduced OVX-induced losses of trabecular bone by 40%, but bone volume in this group was still
reduced from baseline control (p = 0.05). Three months after
OVX, osteoclast surface was similar among all groups (Fig. 3E).
Osteoclasts were present on bone surfaces for both NE-58025
and RIS treatment, consistent with the fact that BPs do not prevent osteoclasts from forming but markedly attenuate their ability to resorb bone. Eroded surface was increased in all groups
compared with baseline animals (Fig. 3F). NE-58025 and RIS
groups exhibited very shallow resorption spaces (Fig. 4). Mineralizing surface increased with OVX and BP treatment (Table 3A).
Cortical bone
Long-term OVX caused endocortical bone loss with an approximately 10% decrease in cortical area fraction versus baseline
control caused by marrow cavity expansion. There were no signiﬁcant changes in total bone area or moment of inertia at midfemoral diaphysis (Table 4A). Treatment with both NE-58025 and
RIS prevented marrow cavity expansion after OVX. There were no
signiﬁcant differences in mineralizing surface or mineral apposition (Table 5A).
Mechanical properties
Whole-bone strength, stiffness, and work to fracture were not
changed signiﬁcantly by OVX (p = 0.4; Table 6A) or by treatment
with either NE-58025 or RIS (p = 0.45 and 0.5, respectively;
Table 6A) compared with baseline control. This ﬁnding was consistent with no changes in total cortical bone area or moment of
inertia noted in μCT studies.

Experiment 2B: Effect of NE-025 and RIS withdrawal after
long-term treatment
Trabecular bone
In these reversal studies, all bone properties observed after withdrawal of NE-58025 or RIS are expressed relative to the bone
parameters at the end of the 3-month-treatment period
(i.e., time zero for reversal). Cessation of NE-58025 treatment in
OVX mice led to the rapid onset of resorption activity and trabecular bone loss. Bone loss occurred quickly after stopping
NE-58025 treatment with BV/TV, and Tb.N decreased by approximately 35% at 1 month posttreatment (p = 0.03; Fig. 5A-C); bone
architecture then remained stable for the duration of the study
period. Osteoclast surface and eroded surface were increased
markedly at 1 month and 2 months posttreatment in NE-58025
mice, respectively (Fig. 5D,E; p = 0.04 and p = 0.02). At 3 months
after stopping NE-58025 treatment, both osteoclast surface and
eroded surface levels were similar to age-matched controls. In
contrast, stopping RIS treatment did not lead to bone loss or
any increase of osteoclast or eroded surfaces during the
3-month posttreatment period (Fig. 5A-E).
Cortical bone
Withdrawal of either BP did not lead to signiﬁcant marrow cavity
expansion/diaphyseal cortical bone loss or increased eroded surface (Tables 4B and 5B). Accordingly, no changes in diaphyseal
mechanical properties were found among bones in the reversal
study (Table 6B).
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Discussion
In the current study, we found that NE-58025, a BP with a low
HAP binding afﬁnity and moderate potency for osteoclast inhibition, successfully suppressed OVX-induced bone loss. Surprisingly, NE-58025 prevented bone loss more effectively than RIS
in this study. Once treatment was stopped, the antiresorptive
effects of NE-58025 reversed very rapidly with increases in osteoclastic activity and bone loss beginning 1 month after ceasing
NE-58025 treatment. This contrasts markedly with the situation
after withdrawing RIS treatment, where neither bone resorption
nor did bone loss resume after stopping treatment during the
3-month course of the reversal study.
Current clinical BPs owe their exceptional efﬁcacy as antiresorptive agents to two major properties: (i) ability to inhibit osteoclastic activity by binding and blocking FPPS, which interferes
with osteoclast resorption of bone, and (ii) moderate-to-high
afﬁnity to bone mineral, which allows them to selectively target
and adhere strongly to bone surfaces in particular at sites of
highest bone turnover. This HAP binding afﬁnity results in very
long functional half-lives for suppression of bone resorption.
Reactivation times for bone resorption after stopping BP treatment are reported to be several months or longer in rodents(52)
and years in humans.(22,23,26,28,53) BPs with low HAP afﬁnity (thus
rapid biological clearance) and potent osteoclast inhibition have
not been developed for clinical use because of their short functional half-lives. However, they may offer potential advantages
with regard to reversibility.(33) The agent we tested in the current
study, NE-58025, is one such compound. The FPPS IC50 for
NE-58025, the concentration needed for 50% inhibition of FPPS
in biochemical assays, has been reported at as 42nM, which is a
relatively high potency in the same general range as zoledronate
and RIS (4.1 and 5.7nM, respectively).(48,67) Whereas, alendronate
has a much lower FPPS inhibition (260nM), but a very high afﬁnity for bone mineral (second only to zoledronate), which allows it
to function as an effective antiresorptive.(47) RIS has the lowest
bone afﬁnity among current clinical BPs.(36,51)
Our test compound, NE-58025, has a different combination
of functional attributes – much lower HAP afﬁnity than any of
the current clinical BPs and high FPPS inhibition.(33,48) This
allowed us to preform proof-of-concept in vivo tests for a
reversible BP with low HAP binding afﬁnity and high FPPS inhibition. The afﬁnity of a BP for bone mineral is typically modulated by the R1 group (i.e., a hydroxyl group for high-afﬁnity
BPs) attached to the P-C-P backbone of the BP to allow for
stronger or weaker binding to the bone.(33,36) In the case of
NE-58025, the R1 substituent is incorporated in a cycloalkyl
ring structure that hinders the binding of the phosphonate
groups to calcium on the bone mineral surface.(33,49,67) The
R2 group of NE-58025 is analogous to that of RIS in that it orients a basic nitrogen moiety similarly for binding to FPPS
enzyme, hence its comparable FPPS inhibition activity and
antiresorptive capabilities.(48) The beneﬁt of the low HAP binding of NE-58025 is the potential for rapid dissolution from
bone. The challenge with such a compound is that it required
daily dosing at a high concentration in these studies to prevent OVX-induced bone loss; dosing 3 times/week did not signiﬁcantly reduce OVX-induced bone loss.
In the current studies, RIS treatment substantially reduced
bone loss long-term after estrogen withdrawal (35% reduction
from baseline BV/TV), as expected. This level of bone loss attenuation is comparable with that reported in numerous previous
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studies using RIS after OVX in rats and mice, even when RIS doses
were much higher (up to 10 times) than those used in the current
study.(68,69) In contrast, NE-58025 at the dose tested completely
stopped bone loss after OVX in our studies. The reasons for this
difference in vivo are not yet completely understood. However,
differences in HAP binding afﬁnity and local bioavailability may
be key.(33) McClung and Ebetino(48) reported that relative afﬁnity
of NE-58025 for bone mineral is substantially lower than RIS (7 vs
10 min, respectively, measured by retention time on an HAP column). Lawson et al(33) report even greater HAP afﬁnity for RIS
(16 min). In other words, RIS adheres more strongly to the
mineral on bone surfaces and should stay more ﬁxed to bone
than NE-58025, which would more readily desorb from bone surfaces. Thus, it seems reasonable to speculate that there is a constant amount of NE-58025 releasing from the bone surfaces that
can be presented to nearby osteoclasts consistently, which
would provide more effective, local dosing at resorbing sites
over time. Further studies are needed to test this idea.
Plotkin, Bellido, and colleagues have shown that BPs can prevent osteocyte apoptosis induced by glucocorticoids(38,70) and
unloading(71), and Follet et al(40) have shown that BP acutely
attenuated osteocyte apoptosis in fatigue-loaded bone. Osteocyte apoptosis has been shown to be a key trigger for the activation of new resorption in response to bone microdamage or
estrogen loss, and inhibition of this apoptosis prevents recruitment and activation of new osteoclasts.(54,72–76) However, we
think it is unlikely that the attenuation of osteocyte apoptosis
by BPs is implicated in the long-term antiresorptive actions of
either RIS or NE-58025 in this study. Follet and colleagues(40)
reported that the BP antiapoptotic effect on osteocytes in their
bone fatigue studies was not sustained for long because osteocyte death increased to nontreated control levels within a week
despite continued BP treatment. Thus, the antiapoptotic effects
of BPs on osteocytes appears to be of short-duration and transient, lasting from days to weeks after a challenge is introduced
to the bone. The current long-term resorption prevention studies
lasted for 3 months after OVX, which is expected to be well after
the acute effects of OVX on triggering osteocyte apoptosis.
Therefore, we assume likewise for potential antiapoptotic effects
of either RIS or NE-58025 and did not examine osteocyte apoptosis in these tissues.
Impaired bone quality (i.e., material properties) after longterm suppression of bone remodeling with BP has been shown
in animal models and in tissues from patients treated long-term
with BPs.(10,12,14,16,77,78) This impairment is hypothesized to drive
the development of AFFs for a small proportion of patients
receiving long-term BP treatment.(12,14,16) In their seminal studies, Mashiba and colleagues(79) found that long-term suppression of bone remodeling with alendronate or RIS treatment in
healthy young adult dogs allowed fatigue microdamage to accumulate in bone with normal daily activities. Bone microdamage
accumulation decreases fracture resistance of the bone material.(80) Suppressed bone turnover also results in increases of
bone matrix mineralization and loss of tissue heterogeneity,
which will also decrease material fracture resistance.(14) In a
recent, remarkable study, Donnelly and coworkers(16) were able
to compare compositional and material properties of femoral
bone samples acquired from BP-treated patients with AFFs to
those from patients with typical osteoporotic fractures both with
and without BP treatment. They found that cortical bone tissue
from BP-treated women with AFF was more highly mineralized
than that from BP-treated women with typical osteoporotic fractures. Furthermore, fracture mechanics studies showed that
JBMR® Plus

tissue from patients treated with BPs had signiﬁcantly reduced
fracture toughness, and the osteonal boundaries were far less
effective at limiting crack growth than bone from BP-naïve
subjects.
A potential solution that has been widely discussed in the clinical literature to mitigate the adverse biomechanical effects of
prolonged suppression of bone remodeling is a so-called drug
holiday. The concept is that a temporary discontinuation of BP
treatment will allow bone turnover to restart and thus remodel
and replace foci of bone that have sustained microdamage or
where material properties have become impaired. Whether this
would actually occur in situ remains unknown. The data to date
regarding the efﬁcacy and usefulness of a BP drug holiday are
confusing and often contradictory. Dennison and colleagues(81)
recently reported that the risk of new fractures could be as much
as 40% higher in subjects who stopped BP treatment caused by
resumed bone loss once long-term suppressed resorption is
reactivated. However, Black and colleagues(22,23) found no difference in nonvertebral osteoporotic fractures when comparing
subjects who continued long-term alendronate treatment with
others who stopped alendronate after an initial 5-year-treatment
period, although they did note an increased risk for clinical vertebral fractures among discontinuers. In a recent large population
cohort study, Adams and colleagues(82) found that women who
took a holiday from BP treatment after 3 or more years did not
appear to be at increased risk of osteoporosis-related fragility
fracture, hip, or vertebral fractures compared with ongoing BP
users.
Studies reviewing the effects of a BP drug holiday on the incidence of AFF have more consistent results. In their large cohort
study, Adams et al(82) found that the incidence of AFF was significantly higher in BP users (mostly treated with alendronate), who
continued versus discontinued use of the drug, suggesting a
strong beneﬁt of a drug holiday. Similarly, Anagnostis et al(83)
examined AFF cases and controls (i.e., conventional subtrochanteric or other osteoporotic fractures) and found that after BP
withdrawal the risk of AFF was reduced by 72% per year after last
use of the drug. Such results are intriguing and could imply that
renewed bone remodeling may indeed be beneﬁcial in repairing
the bone material defects that result from long-term remodeling
suppression. However, the fundamental question of whether
bone quality can be restored by a BP drug holiday remains unanswered and awaits future study.
Although the data regarding the issue of discontinuing BPs
remain contradictory, recent clinical and animal studies show
that stopping the antiresorptive denosumab results in an
increase in bone resorption markers, and in some cases resumed
bone loss to levels that surpass pretreatment with rebound vertebral fractures observed in some postmenopausal woman after
discontinuation of denosumab.(84–87) In the current studies,
NE-58025 discontinuation resulted in a rapid increase in osteoclast surface and eroded surface, followed by a decrease in BV/TV
to values slightly lower than baseline controls after 3 months of
stopping treatment. However, resorption indices at this time
were reduced to age-matched control level, suggesting that
NE-58025 reversal might reach a steady state within a few
months after stopping treatment.
A BP that is both effective at preventing bone loss and rapidly
reversible, such as NE-58025, may have clinical use as an antiresorptive agent with an on/off proﬁle of weeks rather than
months to years—time frames typical of currently used BPs,
including alendronate and RIS. In addition to use in osteoporosis,
lower afﬁnity antiresorptive agents may also be useful in the
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treatment of other bone diseases with high levels of bone
resorption, such as rheumatoid arthritis and oncology, including
the potential prevention of various cancers.(3,88) Our studies
showed that NE-58025 needed to be administered daily to
completely prevent bone loss. This seems unlikely to be well tolerated by patients. However, there are other methods
(i.e., nanoparticle systems or sustained release capsules) that
could be explored to increase the half-lives of these drugs and
ﬁnd the best functional compromise between sustained action
and rapid reversibility. These studies are the ﬁrst to our knowledge to show the antiresorptive capabilities and rapid reversibility of a low HAP afﬁnity BP. Based on these ﬁndings, it is
reasonable to conclude that low HAP afﬁnity/high FPPS potency
BPs might be further explored for clinical use. The rapid reversal
of antiresorptive effects after stopping treatment with NE-58025
may prove to be advantageous by providing insight into
whether a drug holiday can actually improve bone quality and
testing whether reactivated remodeling can in fact restore bone
material properties and ultimately decrease the risk of AFF. This
group of BPs may prove valuable for exploring the biomechanical and compositional effects of a drug holiday, as well as titrating the duration of a drug holiday. Such insights could have
the potential to alter clinical paradigms for treating osteoporosis
in patients and decrease the incidence of AFF.
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